Antitumor Activity of BRAF Inhibitor and IFN{alpha} Combination in BRAF-Mutant Melanoma

Conclusions:
The described results provide a strong rationale for the clinical trials implemented in BRAFV600E melanoma patients with BRAF-I and IFNα combination.

Source: JNCI - February 5, 2016 Category: Cancer & Oncology Authors: Sabbatino, F., Wang, Y., Scognamiglio, G., Favoino, E., Feldman, S. A., Villani, V., Flaherty, K. T., Nota, S., Giannarelli, D., Simeone, E., Anniciello, A. M., Palmieri, G., Pepe, S., Botti, G., Ascierto, P. A., Ferrone, C. R., Ferrone, S. Tags: Article Source Type: research